QM · rank #17 · 2026-10-21
ETON
NASDAQ · $1.43B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +201.58% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +36.0% |
| Profit margin Net profit margin, trailing 12 months. | +12.0% |
| Market cap (USD) Size filter: > $500M required. | $1.43B |
| Anchor (recent) Close on 2026-09-21 | $55.31 |
| Anchor (far) Close on 2025-09-19 | $18.34 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Eton Pharmaceuticals is a rare-disease commercialization platform with eleven commercial products, exclusive U.S. rights to key assets including IMPAVIDO and LIBERVANT, and a pipeline anchored by licensed and acquired specialty drugs.
Rationale
The momentum_12_1 of 2.02 and ROE of 36% are directly supported by a real fundamental inflection — Q2 revenue nearly doubled YoY, management raised 2026 guidance to $145M+, and IMPAVIDO's commercial launch provides near-term revenue visibility that justifies both the price trend and the quality signal.
Material risks
- 1ETON's revenue concentration in licensed products means a supply disruption, licensor renegotiation, or loss of exclusivity on IMPAVIDO or LIBERVANT could instantly remove a disproportionate share of guided revenue with no proprietary fallback.
- 2LIBERVANT's contribution to the $145M guidance trajectory depends on final FDA approval and an April 2027 launch timeline — a regulatory delay or rejection would force a guidance cut and likely break the momentum signal.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.